GT Biopharma Inc - Çeyreklik Finansal İstatistikler (NASDAQ:GTBP) | MetaTrader

Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit -2.47 M-2.2 M-3.01 M-3.68 M-4.02 M -12.91 M Yatırım faaliyetlerinden elde edilen nakit 1 0000000 0 Finansman faaliyetlerinden elde edilen nakit 0616 K5.88 M977 K8.3 M 15.78 M Free cash flow -2.47 M-2.2 M-3.01 M-3.68 M-4.02 M -12.91 M

Haberler

GT Biopharma, Minnesota Üniversitesi ile faz 1 denemesi için anlaştı

GT Biopharma 2025 mali tablolarını yeniden düzenleyecek

GT Biopharma to restate 2025 financials after error in Greenshoe Rights accounting

GT Biopharma, katı tümör kanseri tedavisi için IND başvurusunu sundu

GT Biopharma submits IND application for solid tumor cancer treatment

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment - GT Biopharma (NASDAQ:GTBP)

GT Biopharma hisseleri, Faz 1 denemesi daha yüksek doza ilerlerken yükseldi

GT Biopharma stock rises as Phase 1 trial advances to higher dose

Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Cycurion (NASDAQ:CYCU), Clearwater Analytics Hldg (NYSE:CWAN)

GT Biopharma advances to Cohort 4 in Phase 1 trial of cancer therapy

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Apogee Therapeutics (NASDAQ:APGE), Ambow Education Holding (AMEX:AMBO)

EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - GT Biopharma (NASDAQ:GTBP)